Research and Markets (http://www.researchandmarkets.com/research/cr9t92/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Leber Congenital Amaurosis (LCA) Overview
  3. Therapeutics Development
  4. Pipeline Products for Leber Congenital Amaurosis (LCA) - Overview
  5. Pipeline Products for Leber Congenital Amaurosis (LCA) - Comparative Analysis
  6. Leber Congenital Amaurosis (LCA) - Therapeutics under Development by Companies
  7. Leber Congenital Amaurosis (LCA) - Therapeutics under Investigation by Universities/Institutes
  8. Leber Congenital Amaurosis (LCA) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Leber Congenital Amaurosis (LCA) - Products under Development by Companies
  13. Leber Congenital Amaurosis (LCA) - Products under Investigation by Universities/Institutes
  14. Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development
  • AmpliPhi Biosciences Corporation
  • ProQR Therapeutics N.V.
  • QLT Inc.
  • Spark Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/cr9t92/leber_congenital